Your browser doesn't support javascript.
loading
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
Pinato, David J; Aguilar-Company, Juan; Ferrante, Daniela; Hanbury, Georgina; Bower, Mark; Salazar, Ramon; Mirallas, Oriol; Sureda, Anna; Plaja, Andrea; Cucurull, Marc; Mesia, Ricard; Townsend, Sarah; Jackson, Amanda; Dalla Pria, Alessia; Newsom-Davis, Thomas; Handford, Jasmine; Sita-Lumsden, Ailsa; Apthorp, Eleanor; Vincenzi, Bruno; Bertuzzi, Alexia; Brunet, Joan; Lambertini, Matteo; Maluquer, Clara; Pedrazzoli, Paolo; Biello, Federica; Sinclair, Alasdair; Bawany, Samira; Khalique, Saira; Rossi, Sabrina; Rogers, Lucy; Murphy, Cian; Belessiotis, Katherine; Carmona-García, M Carmen; Sharkey, Rachel; García-Illescas, David; Rizzo, Gianpiero; Perachino, Marta; Saoudi-Gonzalez, Nadia; Doonga, Kris; Fox, Laura; Roldán, Elisa; Gaidano, Gianluca; Ruiz-Camps, Isabel; Bruna, Riccardo; Patriarca, Andrea; Martinez-Vila, Clara; Cantini, Luca; Zambelli, Alberto; Giusti, Raffaele; Mazzoni, Francesca.
Affiliation
  • Pinato DJ; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK; Division of Oncology, University of Piemonte Orientale, Novara, Italy.
  • Aguilar-Company J; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Ferrante D; Department of Translational Medicine, Unit of Medical Statistics, University of Piemonte Orientale, Novara, Italy.
  • Hanbury G; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
  • Bower M; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • Salazar R; Department of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
  • Mirallas O; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
  • Sureda A; Haematology Department, ICO L'Hospitalet, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
  • Plaja A; Medical Oncology Department, B-ARGO Group, IGTP, Catalan Institute of Oncology-Badalona, Spain.
  • Cucurull M; Medical Oncology Department, B-ARGO Group, IGTP, Catalan Institute of Oncology-Badalona, Spain.
  • Mesia R; Medical Oncology Department, B-ARGO Group, IGTP, Catalan Institute of Oncology-Badalona, Spain.
  • Townsend S; Velindre Cancer Centre, Cardiff, UK.
  • Jackson A; Velindre Cancer Centre, Cardiff, UK.
  • Dalla Pria A; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • Newsom-Davis T; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • Handford J; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Sita-Lumsden A; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Apthorp E; Medical School, King's College London, London, UK.
  • Vincenzi B; Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Bertuzzi A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Brunet J; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
  • Lambertini M; Medical Oncology Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
  • Maluquer C; Haematology Department, ICO L'Hospitalet, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
  • Pedrazzoli P; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.
  • Biello F; Division of Oncology, University of Piemonte Orientale, Novara, Italy.
  • Sinclair A; Cancer Division, University College London Hospitals, London, UK.
  • Bawany S; Cancer Division, University College London Hospitals, London, UK.
  • Khalique S; Cancer Division, University College London Hospitals, London, UK.
  • Rossi S; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Rogers L; Cancer Division, University College London Hospitals, London, UK.
  • Murphy C; Cancer Division, University College London Hospitals, London, UK.
  • Belessiotis K; Cancer Division, University College London Hospitals, London, UK.
  • Carmona-García MC; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
  • Sharkey R; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • García-Illescas D; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
  • Rizzo G; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Perachino M; Medical Oncology Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
  • Saoudi-Gonzalez N; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
  • Doonga K; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • Fox L; Department of Hematology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
  • Roldán E; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
  • Gaidano G; Division of Haematology, University of Piemonte Orientale, Novara, Italy; Maggiore della Carità Hospital, Novara, Italy.
  • Ruiz-Camps I; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Bruna R; Division of Haematology, University of Piemonte Orientale, Novara, Italy; Maggiore della Carità Hospital, Novara, Italy.
  • Patriarca A; Division of Haematology, University of Piemonte Orientale, Novara, Italy; Maggiore della Carità Hospital, Novara, Italy.
  • Martinez-Vila C; Fundació Althaia Manresa, Manresa, Spain.
  • Cantini L; Medical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy.
  • Zambelli A; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Giusti R; Medical Oncology, St Andrea Hospital, Rome, Italy.
  • Mazzoni F; Medical Oncology, Careggi University Hospital, Florence, Italy.
Lancet Oncol ; 23(7): 865-875, 2022 07.
Article in En | MEDLINE | ID: mdl-35660139
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2022 Type: Article Affiliation country: Italy
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2022 Type: Article Affiliation country: Italy